Pregnancy outcome after gestational exposure to the new macrolides: A prospective multi-center observational study

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 141, Issue 1, 2008, Pages 31-34

  Bar Oz, Benjamin ^a   Diav Citrin, Orna ^b   Shechtman, Svetlana ^b   Tellem, Rotem ^c   Arnon, Judith ^b   Francetic, Igor ^d   Berkovitch, Matitiahu ^e   Ornoy, Asher ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d KBC Zagreb   (Croatia)

^e ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Azithromycin; Clarithromycin; Congenital malformations; Macrolides; Pregnancy; Roxithromycin

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ROXITHROMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

EID: 54949157934     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2008.07.008     Document Type: Article

References (16)

1. Heikkinen T., Laine K., Neuvonen P.J., and Ekblad U. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG 107 (2000) 770-775
2. Wilton L.V., Pearce G.L., Martin R.M., et al. The outcome of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 105 (1998) 882-889
3. Sarkar M., Woodland C., Koren G., and Einarson A. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 6 (2006) 18 10.1186/1471-2393-6-18
4. Briggs G.G., Freeman R.K., and Yaffe S.J. Drugs in pregnancy and lactation. 7th ed. (2005), Lippincott Williams and Wilkins, Philadelphia p. 140-2
5. Briggs G.G., Freeman R.K., and Yaffe S.J. Drugs in pregnancy and lactation. 7th ed. (2005), Lippincott Williams and Wilkins, Philadelphia p. 338-40
6. Einarson A., Phillips E., Mawji F., et al. A prospective controlled multicenter study of clarithromycin in pregnancy. Am J Perinatol 15 (1998) 523-525
7. Drinkard C.R., Shatin D., and Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 9 (2000) 549-556
8. Czeizel A.E., Rockenbauer M., Olsen J., and Sorensen H. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand 79 3 (2000) 234-237
9. Paulus W., Sabine S., Karl S., and Frank S. Does roxithromycin affect embryo development?. Reprod Toxicol 20 (2005) 477
10. Chun J.Y., Han J.Y., Ahn H.K., et al. Fetal outcome following roxithromycin exposure in early pregnancy. J Matern Fetal Neonatal Med 19 (2006) 189-192
11. Holmes L.B. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 59 (1999) 1-2
12. Product information. Ery-Tabs Abbott Laboratories; 2000.
13. Briggs G.G., Freeman R.K., and Yaffe S.J. Drugs in pregnancy and lactation. 7th ed. (2005), Lippincott Williams and Wilkins, Philadelphia p. 588-90
14. Czeizel A.E., Rockenbauer M., Sorensen H.T., and Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 13 (1999) 531-536
15. Kallen B.A., and Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17 (2003) 255-261
16. Kallen B.A., Otterblad Olausson P., and Danielsson B.R. Is erythromycin therapy teratogenic in humans?. Reprod Toxicol 20 (2005) 209-214